Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

PLUR vs ANRO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANRO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–2 Matrix Metrics)

ANRO Overall Winner 6-Pillar Tally: PLUR 1 – 4 ANRO (1 Tie) Matrix Metrics: PLUR 2 – 7 ANRO

As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PLUR carries a Unified Composite Score of 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin), whereas ANRO carries 34.3/100 (SELL) at $25.12 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although ANRO compares more favorably head-to-head, both PLUR (28.8/100 SELL) and ANRO (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: PLUR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile ANRO is in a Breakdown options structure phase (RSI 48.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PLUR vs ANRO
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
TTM Revenue $1.0M
Forward P/E 3.6x
Beta / 30D Vol 0.80β · 102% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $1.14 · SMA50: $1.08
ANRO NYSE Head-to-Head Winner
Alto Neuroscience Inc.
Pharmaceutical Preparations
$25.12
-7.37% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.03β · 94% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 15.0 Fund 38.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.0 · SMA20: $24.87 · SMA50: $25.98

6-Pillar Scorecard Institutional Category Breakdown (PLUR 1 – 4 ANRO)

Columns: Metric · PLUR · ANRO
1. Valuation Multiples PLUR
Forward P/E 3.6x N/M
Trailing P/E 3.6x N/M
PEG Ratio N/M N/M
EV / Revenue 44.6x N/M
2. Growth & Scale ANRO
Revenue Growth (YoY) -15.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.0M N/A
Market Cap $15.1M $1.2B
3. Profitability & Quality ANRO
Gross Margin 44.6% N/A
Operating Margin -2454.5% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -1022.0% -46.7%
4. Balance Sheet & Cash Flow ANRO
Cash Generation (TTM) -$22M -$80M
Cash Flow Margin N/A N/A
Net Cash / Leverage $30M Net Debt $301M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANRO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 79.4% (8th %ile)
Put/Call OI Skew N/A 0.04x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PLUR (2) vs ANRO (7)
Institutional Metric PLUR ANRO Criterion Row Edge
Market Capitalization
Scale
$15.1M $1.2B Larger Scale ANRO
Trailing P/E Ratio
Valuation
3.6x N/M Lower Multiple PLUR
Forward P/E Ratio
Valuation
3.6x N/M Lower Multiple PLUR
Revenue Growth (YoY)
Growth
-15.8% +0.0% Higher Growth ANRO
Operating Margin (TTM)
Profitability
-2454.5% 0.0% Higher Margin ANRO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-1022.0% -46.7% Higher ROE ANRO
52-Week Range Position
Momentum
2% ($1–$5) 54% ($11–$37) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
0.80β · 102% Vol 2.03β · 94% Vol Lower Realized Risk ANRO
Unified Institutional Score
Composite Signal
28.8 / 100 (SELL) 34.3 / 100 (SELL) Higher Composite ANRO
Trailing 12M Revenue (USD)
Operating Scale
$1.0M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 44.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$22M ($30M Net Debt) -$80M ($301M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLUR +1.01 pp
PLUR: +11.09% · ANRO: +10.08%
3M Horizon ANRO +18.34 pp
PLUR: -46.34% · ANRO: -28.0%
6M Horizon ANRO +85.36 pp
PLUR: -62.52% · ANRO: +22.84%
1Y Horizon ANRO +182.96 pp
PLUR: -75.53% · ANRO: +107.43%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PLUR vs ANRO. Trailing 12-month operating profitability (PLUR -2454.5% vs ANRO 0.0%) and valuation multiples (PLUR 3.6x vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PLUR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.0M
Gross Margin44.6%
Op. Margin-2454.5%
ROE / Fwd P/E-1022.0% · 3.6x
ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PLUR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PLUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANRO BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 79.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PLUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.1M market capitalization and -2454.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PLUR vs ANRO Key Questions & Quantitative Answers

As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PLUR carries a Unified Composite Score of 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin), whereas ANRO carries 34.3/100 (SELL) at $25.12 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although ANRO compares more favorably head-to-head, both PLUR (28.8/100 SELL) and ANRO (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: PLUR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile ANRO is in a Breakdown options structure phase (RSI 48.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANRO leads the Growth & Scale pillar: PLUR posts -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin), compared with ANRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PLUR generates $1.0M in USD-normalized revenue versus N/A for ANRO. In operating R&D and SG&A reinvestment, PLUR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANRO.

PLUR screens cheaper on headline valuation multiples. PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin), whereas ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLUR (-1022.0% ROE) versus ANRO (-46.7% ROE) capital efficiency.

In options market volatility and institutional positioning, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk). By comparison, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.03β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.